Can self-regulation deliver an ethical commercial literature? A critical reading of the “Good Publication Practice” (GPP3) guidelines for industry-financed medical journal articles

References

• AllTrials Campaign. Accessed 27 November 2018. http://www.alltrials.net/
   Google Scholar
• Barbour, V., D. Burch, F. Godlee, C. Heneghan, R. Lehman, R. Perera, J. S. Ross, and S. Schroter. 2016. “Characterisation Of Trials Where Marketing Purposes Have Been Influential In Study Design: A Descriptive Study.” Trials 17 (1): 31. doi:10.1186/s13063-015-1107-1.
   PubMedGoogle Scholar
• Battisti, Wendy P., Elizabeth Wager, Lise Baltzer, Dan Bridges, Angela Cairns, Christopher I. Carswell, Leslie Citrome, et al. 2015. “Good Publication Practice For Communicating Company-Sponsored Medical Research: GPP3.” Annals Of Internal Medicine 163 (6): 461. doi:10.7326/m15-0288.
   PubMed Web of Science ®Google Scholar
• Berger, V., and S. Alperson. 2009. “A General Framework for the Evaluation of Clinical Trial Quality.” Reviews on Recent Clinical Trials 4 (2): 79–88. doi:10.2174/157488709788186021.
   PubMedGoogle Scholar
• Bero, L. A. 2013. “Why the Cochrane Risk of Bias Tool Should Include Funding Source as a Standard Item.” Cochrane Database of Systematic Reviews. doi:10.1002/14651858.ed000075.
   Web of Science ®Google Scholar
• Cepeda, M. S., J. A. Berlin, S. C. Glasser, W. P. Battisti, and M. J. Schuemie. 2015. “Use of Adjectives in Abstracts When Reporting Results of Randomized, Controlled Trials from Industry and Academia.” Drugs in R&D 15 (1): 85–139. doi:10.1007/s40268-015-0085-9.
   PubMed Web of Science ®Google Scholar
• “CONSORT (Consolidated Standards Of Reporting Trials)”. 2018. Consort-Statement.Org. Accessed 10 October 2018. http://www.consort-statement.org/
   Google Scholar
• Cosgrove, L., S. Vannoy, B. Mintzes, and A. F. Shaughnessy. 2016. “Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation.” Accountability in Research 23 (5): 257–279. doi:10.1080/08989621.2016.1153971.
   PubMed Web of Science ®Google Scholar
• CSE (Council of Science Editors). “White Paper on Promoting Integrity in Scientific Journal Publications, 2018 Update.” 2018. Accessed 10 October 2018. https://www.councilscienceeditors.org/resource-library/editorial-policies/white-paper-on-publication-ethics/ (2012 Update cited in GPP3 no longer available, but relevant section unchanged).
   Google Scholar
• Ehrhardt, S., L. J. Appel, and C. L. Meinert. 2015. “Trends In National Institutes Of Health Funding For Clinical Trials Registered In Clinicaltrials.Gov.” JAMA 314 (23): 2566–2567. doi:10.1001/jama.2015.12206.
   PubMed Web of Science ®Google Scholar
• “FDAAA 801 And The Final Rule”. 2018. Clinicaltrials.Gov. Accessed 10 October 2018. https://www.clinicaltrials.gov/ct2/manage-recs/fdaaa
   Google Scholar
• Fugh-Berman, A. J. 2010. ““The Haunting Of Medical Journals: How Ghostwriting Sold “HRT”“.” Plos Medicine 7 (9): e1000335. doi:10.1371/journal.pmed.1000335.
   PubMed Web of Science ®Google Scholar
• Gattrell, W. T., S. Hopewell, K. Young, P. Farrow, R. White, E. Wager, and C. C. Winchester. 2016. “Professional Medical Writing Support And The Quality Of Randomised Controlled Trial Reporting: A Cross-Sectional Study.” BMJ Open 6 (2): e010329. doi:10.1136/bmjopen-2015-010329.
   PubMed Web of Science ®Google Scholar
• “Ghostwriter.” Oxford British & World English Dictionary. Oxford University Press. Accessed 10 October 2018. http://oxforddictionaries.com/definition/english/ghostwriter?q=ghostwriter
   Google Scholar
• Goldacre, B. 2013. Bad Pharma. How Drug Companies Mislead Doctors and Harm Patients. London: Fourth Estate.
   Google Scholar
• Graf, C., W. P Battisti, D. Bridges, V. Bruce-Winkler, J. M Conaty, J. M Ellison, E. A Field, et al. 2009. “Good Publication Practice For Communicating Company Sponsored Medical Research: The GPP2 Guidelines.” BMJ 339 (nov27 1): b4330–b4330. doi:10.1136/bmj.b4330.
   PubMedGoogle Scholar
• Heres, S., J. Davis, K. Maino, E. Jetzinger, W. Kissling, and S. Leucht. 2006. “Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, And Quetiapine Beats Olanzapine: An Exploratory Analysis Of Head-To-Head Comparison Studies Of Second-Generation Antipsychotics.” American Journal Of Psychiatry 163 (2): 185–194. doi:10.1176/appi.ajp.163.2.185.
   PubMed Web of Science ®Google Scholar
• Hoekman, J., K. Frenken, D. de Zeeuw, and H. L. Heerspink. 2012. “The Geographical Distribution Of Leadership In Globalized Clinical Trials.” PLoS One 7 (10): e45984. doi:10.1371/journal.pone.0045984.
   PubMed Web of Science ®Google Scholar
• ICMJE (International Committee of Medical Journal Editors) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations). 2017 Edition. Accessed 10 October 2018. http://www.icmje.org/recommendations/
   Google Scholar
• ISMPP (International Society for Medical Publications Professionals). ISMPP Initiatives. Accessed 10 October 2018. https://www.ismpp.org/initiatives
   Google Scholar
• ISMPP Governance. Accessed 10 October 2018. https://www.ismpp.org/governance
   Google Scholar
• Jacobs, A., on behalf of the Europe Force. 2005. “The Involvement Of Professional Medical Writers In Medical Publications: Results Of A Delphi Study.” Current Medical Research and Opinion 21 (2): 311–316. doi:10.1185/030079905x25569.
   PubMed Web of Science ®Google Scholar
• Jefferson, T., and J. Lars. 2018. “Redefining The ‘E’ In EBM.” BMJ Evidence-Based Medicine 23 (2): 46–47. doi:10.1136/bmjebm-2018-110918.
   PubMedGoogle Scholar
• Leo, J., J. R. Lacasse, and A. N. Cimino. 2011. “Why Does Academic Medicine Allow Ghostwriting? A Prescription For Reform.” Society 48 (5): 371–375. doi:10.1007/s12115-011-9455-2.
   Web of Science ®Google Scholar
• Lexchin, J. 2012. “Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications.” Science and Engineering Ethics 18 (2): 247–261. doi:10.1007/s11948-011-9265-3.
   PubMed Web of Science ®Google Scholar
• Lundh, A., J. Lexchin, B. Mintzes, J. B. Schroll, and L. Bero. 2018. “Industry Sponsorship And Research Outcome: Systematic Review With Meta-Analysis.” Intensive Care Medicine 44 (10): 1603–1612. doi:10.1007/s00134-018-5293-7.
   PubMed Web of Science ®Google Scholar
• Matheson, A. 2008. “Corporate Science And The Husbandry Of Scientific And Medical Knowledge By The Pharmaceutical Industry.” Biosocieties 3 (4): 355–382. doi:10.1017/s1745855208006297.
   Web of Science ®Google Scholar
• Matheson, Alastair. 2011. “How Industry Uses the ICMJE Guidelines to Manipulate Authorship—And How They Should Be Revised.” PLoS Medicine 8(8). doi:10.1371/journal.pmed.1001072.
   Web of Science ®Google Scholar
• Matheson, A. 2016a. “Ghostwriting: The Importance of Definition and Its Place in Contemporary Drug Marketing.” BMJ i4578. doi:10.1136/bmj.i4578.
   PubMedGoogle Scholar
• Matheson, A. 2016b. “The Disposable Author: How Pharmaceutical Marketing Is Embraced within Medicine’s Scholarly Literature.” Hastings Center Report 46 (4): 31–37. doi:10.1002/hast.576.
   PubMed Web of Science ®Google Scholar
• Matheson, A. 2016c. “The ICMJE Recommendations and Pharmaceutical Marketing – Strengths, Weaknesses and the Unsolved Problem of Attribution in Publication Ethics.” BMC Medical Ethics 17 (1). doi:10.1186/s12910-016-0103-7.
   PubMedGoogle Scholar
• Matheson, A. 2016d. “Attribution, Advocacy, Disposable Authors, Corporate Ghosts and Cultural Assimilation: New Themes in the Ethical Critique of Commercial Medical Literature.” Medical Writing 25 (1)(2016): 25–30. Accessed 16 January 2019. https://journal.emwa.org/authors-and-authorship/attribution-advocacy-disposable-authors-corporate-ghosts-and-cultural-assimilation-new-themes-in-the-ethical-critique-of-commercial-medical-literature/.
   Google Scholar
• Matheson, A. 2017. “Marketing Trials, Marketing Tricks — How to Spot Them and How to 740 Stop Them.” Trials 18 (1): 105. doi:10.1186/s13063-017-1827-5.
   PubMedGoogle Scholar
• McHenry, L. B., and J. N. Jureidini. 2008. “Industry-Sponsored Ghostwriting in Clinical Trial Reporting: A Case Study.” Accountability in Research 15 (3): 152–167. doi:10.1080/08989620802194384.
   PubMed Web of Science ®Google Scholar
• Moynihan, R. 2008. “Key Opinion Leaders: Independent Experts or Drug Representatives in Disguise?” BMJ 336 (7658): 1402–1403. doi:10.1136/bmj.39575.675787.651.
   PubMed Web of Science ®Google Scholar
• Prasad, V., and V. W. Berger. 2015. “Hard-Wired Bias.” Mayo Clinic Proceedings 90 (9): 1171–1175. doi:10.1016/j.mayocp.2015.05.006.
   PubMedGoogle Scholar
• Rasmussen, K., L. Bero, R. Redberg, P. C. Gøtzsche, and A. Lundh. 2018. “Collaboration Between Academics And Industry In Clinical Trials: Cross Sectional Study Of Publications And Survey Of Lead Academic Authors.” BMJ k3654. doi:10.1136/bmj.k3654.
   PubMedGoogle Scholar
• Rochon, Paula A, Melanie Sekeres, John Hoey, Joel Lexchin, Lorraine E Ferris, David Moher, Wei Wu, et al. 2011. “Investigator Experiences With Financial Conflicts Of Interest In Clinical Trials.” Trials 12 (1). doi:10.1186/1745-6215-12-9.
   Google Scholar
• Rose, S. L., M. K. Krzyzanowska, and S. Joffe. 2010. “Relationships Between Authorship Contributions And Authors’ Industry Financial Ties Among Oncology Clinical Trials.” Journal Of Clinical Oncology 28 (8): 1316–1321. doi:10.1200/jco.2008.21.6606.
   PubMed Web of Science ®Google Scholar
• Ross, J. S., K. P. Hill, D. S. Egilman, and H. M. Krumholz. 2008. “Guest Authorship and Ghostwriting in Publications Related to Rofecoxib.” JAMA 299 (15): 1800. doi:10.1001/jama.299.15.1800.
   PubMed Web of Science ®Google Scholar
• Sismondo, S. 2009. “Ghosts in the Machine.” Social Studies of Science 39 (2): 171–198. doi:10.1177/0306312708101047.
   PubMed Web of Science ®Google Scholar
• Sismondo, S. 2015. “Key Opinion Leaders.” Value Practices in the Life Sciences and Medicine 31–48. doi:10.1093/acprof:oso/9780199689583.003.0002.
   Google Scholar
• Sismondo, S., and S. H. Nicholson. 2009. “Publication Planning 101.” Journal of Pharmacy & Pharmaceutical Sciences 12 (3): 273. doi:10.18433/j3ww2r.
   PubMed Web of Science ®Google Scholar
• Smith, R. 2005. “Medical Journals Are An Extension Of The Marketing Arm Of Pharmaceutical Companies.” Plos Medicine 2 (5): e138. doi:10.1371/journal.pmed.0020138.
   PubMed Web of Science ®Google Scholar
• Wager, E., E. A. Field, and L. Grossman. 2003. “Good Publication Practice For Pharmaceutical Companies.” Current Medical Research And Opinion 19 (3): 149–154. doi:10.1185/030079903125001767.
   PubMed Web of Science ®Google Scholar
• “White Paper: Key Opinion Leader Identification and Selection. A Pharma Matters Report. Thomson Reuters, January 2009.” Accessed 10 October 2018. http://www.slideshare.net/driceman/kol-management?related=1
   Google Scholar
• Wittek, M. R., M. J. Williams, and A. M. Carlson. 2009. “Evidence Development And Publication Planning: Strategic Process.” Current Medical Research And Opinion 25 (11): 2723–2727. doi:10.1185/03007990903297782.
   PubMed Web of Science ®Google Scholar
• Woolley, K. L., R. A. Lew, S. Stretton, J. A. Ely, N. J. Bramich, J. R. Keys, J. A. Monk, and M. J. Woolley. 2011. “Lack Of Involvement Of Medical Writers And The Pharmaceutical Industry In Publications Retracted For Misconduct: A Systematic, Controlled, Retrospective Study.” Current Medical Research And Opinion 27 (6): 1175–1182. doi:10.1185/03007995.2011.573546.
   PubMed Web of Science ®Google Scholar
• World Health Organization. “WHO Statement on Public Disclosure of Clinical Trial Results.” Accessed 10 October 2018. http://www.who.int/ictrp/results/WHO_Statement_results_reporting_clinical_trials.pdf?ua=1
   Google Scholar
• World Medical Association. 2013. “World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects.” JAMA 310 (20): 2191. doi:10.1001/jama.2013.281053.
   PubMed Web of Science ®Google Scholar